^
Association details:
| Biomarker: | KRT17 overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockadev
Published date:
05/27/2022
Excerpt:
In a cohort of patients with HNSCC receiving pembrolizumab, high K17 expression correlated with poor response....We demonstrate that K17 expression in HNSCC contributes to immune evasion and resistance to ICB treatment by broadly altering immune landscapes of tumors.
DOI:
10.1158/1078-0432.CCR-21-3039
